Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274038 · ClinicalTrials.gov registry record · NA
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
A NA study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02274038: Clinical Trial NA study, sponsored by University of Pennsylvania.
NCT02274038 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02274038, a NA study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer (NSCLC).
Interventions
- DRUG Baseline 18F-thymidine (FLT) PET/CT
- DRUG Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare"
- DRUG Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02274038
The ClinicalTrials.gov registry entry for NCT02274038 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Baseline 18F-thymidine (FLT) PET/CT is the first listed.
NCT02274038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02274038 about?
NCT02274038 is a clinical study titled "Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer". The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer (NSCLC).
What is the current status of trial NCT02274038?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2015-03. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02274038?
The interventions under investigation include: Baseline 18F-thymidine (FLT) PET/CT (DRUG), Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare" (DRUG), Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation (DRUG).
Who is sponsoring clinical trial NCT02274038?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.